Assertio Holdings (NASDAQ: ASRT) revises ROLVEDON supply deal with long-term pricing shift

Rhea-AI Filing Summary

Assertio Holdings, through its subsidiary Spectrum Pharmaceuticals, amended and restated its supply agreement with Hanmi Pharmaceutical for the ROLVEDON drug substance. The change, effective after the fixed pricing provisions expire in October 2025, sets long‑term pricing that includes a mid‑single digit percentage reduction to the price agreed after Assertio acquired Spectrum in 2023.

The new price remains fixed for the rest of Spectrum’s license term with Hanmi, while allowing Hanmi to request price increases for periods beginning January 1, 2028 if its costs rise above a set threshold. The amendment also adds a volume-based feature that reduces per‑gram pricing in years when the prior year’s global market volume passes a specified level. Spectrum must provide annual purchase forecasts, and at least fifty percent of forecasted orders must be binding, though there are no minimum purchase requirements. Other supply terms were not materially changed.

Insights

Pharmaceutical supply & margins analyst

Assertio secures modest long‑term ROLVEDON cost reduction with added volume and cost‑based adjustments.

The amendment locks in a mid‑single digit percentage price cut for ROLVEDON drug substance relative to the level agreed after Assertio’s 2023 Spectrum acquisition. Fixing this lower price for the remaining term of Spectrum’s license with Hanmi can support product gross margins, subject to the later adjustment mechanisms described.

From January 2028, Hanmi may request price increases if its costs rise above a defined threshold, while a separate provision reduces per‑gram pricing for years when the prior year’s global market volume exceeds a specified trigger. This creates a balance between supplier cost protection and buyer volume incentives. Spectrum’s consent is required for manufacturing process changes, giving it leverage to negotiate further price reductions when process improvements lower Hanmi’s costs.

The requirement for annual forecasted purchase plans, with at least fifty percent of included orders designated as binding, improves planning coordination without imposing minimum purchase commitments. Future disclosures in the company’s 2025 Form 10‑K, where the full amendment will be filed as an exhibit, may provide additional operational details.

8-K Event Classification

Item 1.01 — Entry into a Material Definitive Agreement

1 item

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Understanding 8-K Material Events →

false 0001808665 0001808665 2025-10-07 2025-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

October 7, 2025

ASSERTIO HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39294		85-0598378
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 South Saunders Rd., Suite 300,

Lake Forest, IL 60045

(Address of principal executive offices, including zip code)

(224) 419-7106

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

	Title of each class:		Trading Symbol(s):		Name of each exchange on which registered:
	Common Stock, $0.0001 par value		ASRT		The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive Agreement.

On October 7, 2025, Spectrum Pharmaceuticals, Inc. (“Spectrum”), a wholly owned subsidiary of Assertio Holdings, Inc. (the “Company”), and Hanmi Pharmaceutical Co. Ltd. (the “Supplier”) entered into an amendment and restatement (the “Amendment”) of the Supply Agreement dated February 28, 2018, as previously amended, which provides for the supply of ROLVEDON drug substance to Spectrum (the “Agreement”). Among other things, the Amendment establishes long-term pricing following the expiration of the Agreement’s fixed pricing provisions in October 2025.

The Amendment reflects a mid-single digit percentage reduction to the price Spectrum agreed to pay the Supplier for ROLVEDON drug substance following the Company’s acquisition of Spectrum in 2023. Pursuant to the Amendment, the new price is fixed throughout the remaining term of Spectrum’s license agreement with the Supplier, subject to (1) the Supplier’s right to request price increases for periods beginning January 1, 2028, to the extent it experiences cost increases above a set threshold, and (2) a provision that reduces the per gram pricing by a specified amount for each year in which the previous year’s global market volume for ROLVEDON exceeds a specified threshold which has not yet been met. Spectrum’s consent is required for any changes to Supplier’s manufacturing process. Accordingly, Spectrum may seek to negotiate a lower supply price as a condition to its approval of any future process improvements that lower the Supplier’s costs.

Pursuant to the Amendment, Spectrum will also be required to provide the Supplier with a forecasted purchase plan each year. While there are no minimum purchase requirements, if Spectrum includes any orders in a forecasted purchase plan, it must designate at least fifty percent of such orders as binding. None of the Agreement’s other supply terms were materially amended.

The foregoing summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ending December 31, 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 10, 2025

ASSERTIO HOLDINGS, INC.

/s/ Brendan P. O’Grady

Brendan P. O’Grady

Chief Executive Officer

FAQ

What agreement did Assertio Holdings (ASRT) update in this 8-K?

Assertio, through its subsidiary Spectrum Pharmaceuticals, entered into an amendment and restatement of the ROLVEDON drug substance Supply Agreement with Hanmi Pharmaceutical, originally dated February 28, 2018 and previously amended.

How does the amended ROLVEDON supply agreement affect pricing for ASRT?

The amendment establishes long‑term pricing after the fixed pricing ends in October 2025 and includes a mid‑single digit percentage reduction to the price Spectrum agreed to pay for ROLVEDON drug substance following Assertio’s 2023 acquisition of Spectrum.

Can Hanmi Pharmaceutical raise prices under the new ROLVEDON agreement with ASRT?

Yes. Starting with periods beginning January 1, 2028, Hanmi may request price increases if it experiences cost increases above a specified threshold, as permitted by the amendment.

What volume-based pricing feature was added for ROLVEDON in the ASRT agreement?

The amendment includes a provision that reduces per gram pricing by a specified amount for each year in which the previous year’s global market volume for ROLVEDON exceeds a defined threshold that has not yet been met.

What forecasting and purchasing commitments does Spectrum have under the amended agreement?

Spectrum must provide an annual forecasted purchase plan to Hanmi. There are no minimum purchase requirements, but for any orders included in a forecast, at least 50% must be designated as binding.

Does Spectrum have influence over Hanmi’s manufacturing changes under this amended deal?

Yes. Spectrum’s consent is required for any changes to Hanmi’s manufacturing process. Spectrum may seek to negotiate a lower supply price as a condition to approving future process improvements that reduce Hanmi’s costs.

Where will investors find the full text of the amended ROLVEDON supply agreement?

Assertio states that the amendment will be filed as an exhibit to its Annual Report on Form 10‑K for the year ending December 31, 2025, which will provide the complete contract terms.